Top

Published in:

01-12-2021 | Ovarian Cancer | Research article

Genetic alterations and their therapeutic implications in epithelial ovarian cancer

Authors: Nina Lapke, Chien-Hung Chen, Ting-Chang Chang, Angel Chao, Yen-Jung Lu, Chyong-Huey Lai, Kien Thiam Tan, Hua-Chien Chen, Hsiao-Yun Lu, Shu-Jen Chen

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Genetic alterations for epithelial ovarian cancer are insufficiently characterized. Previous studies are limited regarding included histologies, gene numbers, copy number variant (CNV) detection, and interpretation of pathway alteration patterns of individual patients.

Methods

We sequenced 410 genes to analyze mutations and CNV of 82 ovarian carcinomas, including high-grade serous (n = 37), endometrioid (n = 22) and clear cell (n = 23) histologies. Eligibility for targeted therapy was determined for each patient by a pathway-based approach. The analysis covered DNA repair, receptor tyrosine kinase, PI3K/AKT/MTOR, RAS/MAPK, cell cycle, and hedgehog pathways, and included 14 drug targets.

Results

Postulated PARP, MTOR, and CDK4/6 inhibition sensitivity were most common. BRCA1/2 alterations, PTEN loss, and gain of PIK3CA and CCND1 were characteristic for high-grade serous carcinomas. Mutations of ARID1A, PIK3CA, and KRAS, and ERBB2 gain were enriched in the other histologies. PTEN mutations and high tumor mutational burden were characteristic for endometrioid carcinomas. Drug target downstream alterations impaired actionability in all histologies, and many alterations would not have been discovered by key gene mutational analysis. Individual patients often had more than one actionable drug target.

Conclusions

Genetic alterations in ovarian carcinomas are complex and differ among histologies. Our results aid the personalization of therapy and biomarker analysis for clinical studies, and indicate a high potential for combinations of targeted therapies.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017;109(9):djx030. https://doi.org/10.1093/jnci/djx030. PMID: 28376154; PMCID: PMC5409140.

Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–60.

Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88(11):2584–9. https://doi.org/10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.CrossRefPubMed

Ku FC, Wu RC, Yang LY, Tang YH, Chang WY, Yang JE, Wang CC, Jung SM, Lin CT, Chang TC, et al. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study. J Formos Med Assoc. 2017;117(2):117–25.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744–50. https://doi.org/10.1038/s41591-019-0407-5.CrossRefPubMedPubMedCentral

Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of Biomarker-Based Treatment Strategies with Response Rates and Progression-Free Survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2(11):1452–9. https://doi.org/10.1001/jamaoncol.2016.2129.CrossRefPubMed

Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18(23):6509–18. https://doi.org/10.1158/1078-0432.CCR-12-1796.CrossRefPubMed

Matulonis UA, Sill M, Thaker PH, Carlson JW, Darus CJ, Mannel RS, et al. NRG/GOG 186K: a randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—final results. Gynecol Oncol. 2016;141:207. https://doi.org/10.1016/j.ygyno.2016.04.533.CrossRef

10.

Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730–8. https://doi.org/10.1158/1078-0432.CCR-14-1814.CrossRefPubMed

11.

Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012;126(1):47–53. https://doi.org/10.1016/j.ygyno.2012.04.006.CrossRefPubMedPubMedCentral

12.

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol Oncol. 2017;144(2):250–5. https://doi.org/10.1016/j.ygyno.2016.12.002.CrossRefPubMed

13.

Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. https://doi.org/10.1038/nature10166.CrossRef

14.

Friedlander ML, Russell K, Millis S, Gatalica Z, Bender R, Voss A. Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials. Int J Gynecol Cancer. 2016;26(4):648–54. https://doi.org/10.1097/IGC.0000000000000677.CrossRefPubMedPubMedCentral

15.

McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014;27(1):128–34. https://doi.org/10.1038/modpathol.2013.107.CrossRefPubMed

16.

Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64(21):7678–81. https://doi.org/10.1158/0008-5472.CAN-04-2933.CrossRefPubMed

17.

Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol. 2007;38(4):607–13. https://doi.org/10.1016/j.humpath.2006.10.007.CrossRefPubMed

18.

Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–601. https://doi.org/10.2353/ajpath.2009.081000.CrossRefPubMedPubMedCentral

19.

Maru Y, Tanaka N, Ohira M, Itami M, Hippo Y, Nagase H. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynecol Oncol. 2017;144(2):377–83. https://doi.org/10.1016/j.ygyno.2016.11.045.CrossRefPubMed

20.

Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, et al. Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genet. 2012;5(1):47. https://doi.org/10.1186/1755-8794-5-47.CrossRef

21.

Elvin JA, Chura J, Gay LM, Markman M. Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options. Gynecol Oncol Rep. 2017;20:62–6.CrossRefPubMedPubMedCentral

22.

Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5(1):3156. https://doi.org/10.1038/ncomms4156.CrossRefPubMed

23.

Hsu H-C, Lapke N, Chen S-J, Lu Y-J, Jhou R-S, Yeh C-Y, Tsai W-S, Hung H-Y, Hsieh JC-H, Yang T-S et al: PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. Cancers. 2018;10(9):314.

24.

Chao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, et al. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 2016;7(51):85529–41. https://doi.org/10.18632/oncotarget.13456.CrossRefPubMedPubMedCentral

25.

Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 2014;30(24):3443–50.CrossRefPubMedPubMedCentral

26.

Amarasinghe KC, Li J, Hunter SM, Ryland GL, Cowin PA, Campbell IG, et al. Inferring copy number and genotype in tumour exome data. BMC Genomics. 2014;15(1):732. https://doi.org/10.1186/1471-2164-15-732.CrossRefPubMedPubMedCentral

27.

Francies H, McDermott U, Garnett M. Genomics-guided pre-clinical development of cancer therapies. Nat Cancer. 2020;1(5):482–92. https://doi.org/10.1038/s43018-020-0067-x.CrossRefPubMed

28.

Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50.CrossRefPubMed

29.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708. https://doi.org/10.1056/NEJMoa1506859.CrossRefPubMedPubMedCentral

30.

Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752–67. https://doi.org/10.1158/2159-8290.CD-14-0849.CrossRefPubMedPubMedCentral

31.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–22. https://doi.org/10.1002/emmm.200900041.CrossRefPubMedPubMedCentral

32.

Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013;34(4):739–49. https://doi.org/10.1093/carcin/bgs393.CrossRefPubMed

33.

Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene. 2013;32(47):5377–87. https://doi.org/10.1038/onc.2013.311.CrossRefPubMed

34.

Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, et al. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget. 2017;8(25):40152–68. https://doi.org/10.18632/oncotarget.10308.CrossRefPubMed

35.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.CrossRefPubMed

36.

Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, et al. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol. 2016;141(1):57–64. https://doi.org/10.1016/j.ygyno.2016.01.004.CrossRefPubMedPubMedCentral

37.

Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly (ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010;70(13):5389–98. https://doi.org/10.1158/0008-5472.CAN-09-4716.CrossRefPubMed

38.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer group, and gynecologic Cancer intergroup study. J Clin Oncol. 2014;32(4):320–6. https://doi.org/10.1200/JCO.2013.50.5669.CrossRefPubMed

39.

Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study. Gynecol Oncol. 2008;108(3):493–9. https://doi.org/10.1016/j.ygyno.2007.11.029.CrossRefPubMedPubMedCentral

40.

Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28(7):1215–23. https://doi.org/10.1200/JCO.2009.22.3354.CrossRefPubMed

41.

Kaye SB, Poole CJ, Danska-Bidzinska A, Gianni L, Del Conte G, Gorbunova V, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol. 2013;24(1):145–52. https://doi.org/10.1093/annonc/mds282.CrossRefPubMed

42.

du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–82. https://doi.org/10.1200/JCO.2014.55.7348.CrossRefPubMed

43.

Harb WA, Sessa C, Hirte HW, Kaye SB, Banerjee SN, Christinat A, Simantov R, Singh M, Sternberg DW, Light R, et al. Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. J Clin Oncol. 2013;31(15_suppl):e13502–e13502.

44.

Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Women Health. 2016;12(3):363–78. https://doi.org/10.2217/whe.16.4.CrossRef

45.

Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34(1):4–16. https://doi.org/10.5732/cjc.014.10289.CrossRefPubMedPubMedCentral

46.

Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499–502. https://doi.org/10.1126/science.1162981.CrossRefPubMedPubMedCentral

47.

Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31. https://doi.org/10.1158/1535-7163.MCT-13-0639.CrossRefPubMed

48.

Mieulet V, Lamb RF. Tuberous sclerosis complex: linking cancer to metabolism. Trends Mol Med. 2010;16(7):329–35. https://doi.org/10.1016/j.molmed.2010.05.001.CrossRefPubMed

49.

Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat Rev Urol. 2015;12(10):558–69. https://doi.org/10.1038/nrurol.2015.206.CrossRefPubMedPubMedCentral

50.

Petrilli AM, Fernandez-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537–48. https://doi.org/10.1038/onc.2015.125.CrossRefPubMed

51.

Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77–86. https://doi.org/10.1158/1078-0432.CCR-14-0947.CrossRefPubMed

52.

Piha-Paul SA, Taylor MH, Spitz D, Schwartzberg L, Beck JT, Bauer TM, et al. Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. Oncotarget. 2019;10(60):6526–35. https://doi.org/10.18632/oncotarget.27251.CrossRefPubMedPubMedCentral

53.

Takano M, Kouta H, Kudoh K, Kita T, Kikuchi R, Miyamoto M, Yoshikawa T, Goto T, Furuya K, Tamada Y, et al. Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis. J Clin Oncol. 2015;33(15_suppl):5583.

54.

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study. Gynecol Oncol. 2011;123(1):19–26. https://doi.org/10.1016/j.ygyno.2011.06.022.CrossRefPubMedPubMedCentral

55.

Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, et al. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. Int J Oncol. 2015;46(6):2389–98. https://doi.org/10.3892/ijo.2015.2951.CrossRefPubMed

56.

Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, et al. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020;157(1):55–61. https://doi.org/10.1016/j.ygyno.2020.02.011.CrossRefPubMed

57.

Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928–42. https://doi.org/10.1038/nrd4281.CrossRefPubMed

58.

Mullard A. Cracking KRAS. Nat Rev Drug Discov. 2019;18(12):887–91.CrossRefPubMed

59.

Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115. https://doi.org/10.1038/nrc.2016.138.CrossRefPubMedPubMedCentral

60.

Konecny GE, Hendrickson AEW, Jatoi A, Burton JK, Paroly J, Glaspy JA, Dowdy SC, Slamon DJ. A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. J Clin Oncol. 2016;34(15_suppl):5557.

61.

Iyengar M, O'Hayer P, Cole A, Sebastian T, Yang K, Coffman L, et al. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer. Oncotarget. 2018;9(21):15658–72. https://doi.org/10.18632/oncotarget.24585.CrossRefPubMedPubMedCentral

62.

Konecny GE. Cyclin-dependent kinase pathways as targets for women's cancer treatment. Curr Opin Obstet Gynecol. 2016;28(1):42–8. https://doi.org/10.1097/GCO.0000000000000243.CrossRefPubMed

63.

McMillan R, Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res. 2012;18(18):4883–8.CrossRefPubMedPubMedCentral

64.

Katoh Y, Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int J Mol Med. 2006;18(6):1019–23.PubMed

65.

Diebold J, Mosinger K, Peiro G, Pannekamp U, Kaltz C, Baretton GB, et al. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol. 2000;190(5):564–71. https://doi.org/10.1002/(SICI)1096-9896(200004)190:5<564::AID-PATH569>3.0.CO;2-L.CrossRefPubMed

66.

Dimova I, Zaharieva B, Raicheva S, Milev I, Dimitrov R, Doganov N, et al. Association of CyclinD1 copy number changes with histological type in ovarian tumors. Acta Oncol. 2004;43(7):675–9. https://doi.org/10.1080/02841860410018548.CrossRefPubMed

67.

Alsop K, Fereday S, Meldrum C, de Fazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group. J Clin Oncol. 2012;30(21):2654–63. https://doi.org/10.1200/JCO.2011.39.8545.CrossRefPubMedPubMedCentral

68.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–43.CrossRefPubMedPubMedCentral

69.

Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan DSP, et al. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine. 2019;50:203–10. https://doi.org/10.1016/j.ebiom.2019.11.017.CrossRefPubMedPubMedCentral

70.

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–75. https://doi.org/10.1158/1078-0432.CCR-13-2287.CrossRefPubMed

71.

Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen W-J, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol. 2018;2018(2):1–13.

72.

Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, et al. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. Int J Cancer. 2019;145(5):1209–20. https://doi.org/10.1002/ijc.32143.CrossRefPubMed

73.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.CrossRefPubMed

74.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87. https://doi.org/10.1016/S1470-2045(16)30559-9.CrossRefPubMed

75.

Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S. ARID1A mutant ovarian clear cell carcinoma: a clear target for synthetic lethal strategies. Biochim Biophys Acta Rev Cancer. 2018;1870(2):176–84. https://doi.org/10.1016/j.bbcan.2018.07.005.CrossRefPubMed

76.

Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol. 2013;37(9):1342–8. https://doi.org/10.1097/PAS.0b013e3182889dc3.CrossRefPubMedPubMedCentral

77.

Suryo Rahmanto Y, Shen W, Shi X, Chen X, Yu Y, Yu ZC, et al. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nat Commun. 2020;11(1):2717. https://doi.org/10.1038/s41467-020-16416-0.CrossRefPubMedPubMedCentral

78.

Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun. 2013;4(1):2578. https://doi.org/10.1038/ncomms3578.CrossRefPubMed

79.

Dang VT, Kassahn KS, Marcos AE, Ragan MA. Identification of human haploinsufficient genes and their genomic proximity to segmental duplications. Eur J Hum Genet. 2008;16(11):1350–7.CrossRefPubMed

80.

Manikandan M, Raksha G, Munirajan AK. Haploinsufficiency of tumor suppressor genes is driven by the cumulative effect of microRNAs, microRNA binding site polymorphisms and microRNA polymorphisms: an in silico approach. Cancer Informat. 2012;11:157–71.CrossRef

81.

Kurzhals RL, Titen SW, Xie HB, Golic KG. Chk2 and p53 are haploinsufficient with dependent and independent functions to eliminate cells after telomere loss. PLoS Genet. 2011;7(6):e1002103.CrossRefPubMedPubMedCentral

82.

Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3(1):35–43.CrossRefPubMed

83.

Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454–8. https://doi.org/10.1038/ng.556.CrossRefPubMedPubMedCentral

84.

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50. https://doi.org/10.1038/s41568-019-0116-x.CrossRefPubMedPubMedCentral

85.

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https://doi.org/10.1186/s13073-017-0424-2.CrossRefPubMedPubMedCentral

86.

Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013;73(1):276–84. https://doi.org/10.1158/0008-5472.CAN-12-1726.CrossRefPubMed

87.

Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6(2):377–87.CrossRefPubMedPubMedCentral

88.

Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI (3) Kalpha inhibitor. Nature. 2015;518(7538):240–4. https://doi.org/10.1038/nature13948.CrossRefPubMed

89.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13(5):1117–29.CrossRefPubMed

90.

Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, et al. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget. 2016;7(9):10547–56.CrossRefPubMedPubMedCentral

91.

Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–40. https://doi.org/10.1016/S1470-2045(12)70572-7.CrossRefPubMedPubMedCentral

92.

Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G. Trametinib response in heavily pretreated high-grade ovarian cancer: one step towards precision medicine. Gynecol Oncol Rep. 2020;32:100547. https://doi.org/10.1016/j.gore.2020.100547.CrossRefPubMedPubMedCentral

93.

Courtney E, Chan SH, Li ST, Ishak D, Merchant K, Shaw T, et al. Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1. Familial Cancer. 2020;19(4):353–8. https://doi.org/10.1007/s10689-020-00184-3.CrossRefPubMed

94.

Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, et al. BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Disc. 2021;11(1):142–57.

95.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer cell. 2015;27(1):85–96. https://doi.org/10.1016/j.ccell.2014.11.006.CrossRefPubMedPubMedCentral

96.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640–5. https://doi.org/10.1093/annonc/mdx784.CrossRefPubMed

97.

Barroso-Sousa R, Guo H, Barry WT, Ferreira AR, Rees R, Winer EP, et al. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis. J Clin Oncol. 2018;36(15_suppl):1068.CrossRef

98.

Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer cell. 2015;27(3):327–41. https://doi.org/10.1016/j.ccell.2015.02.001.CrossRefPubMedPubMedCentral

99.

Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, et al. Epigenetic targeting of hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014;20(7):732–40. https://doi.org/10.1038/nm.3613.CrossRefPubMedPubMedCentral

Title: Genetic alterations and their therapeutic implications in epithelial ovarian cancer
Authors: Nina Lapke
Chien-Hung Chen
Ting-Chang Chang
Angel Chao
Yen-Jung Lu
Chyong-Huey Lai
Kien Thiam Tan
Hua-Chien Chen
Hsiao-Yun Lu
Shu-Jen Chen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Targeted Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08233-5

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes

Head and neck squamous cell carcinoma cell lines have an immunomodulatory effect on macrophages independent of hypoxia and toll-like receptor 9

Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma